BriefReport:LamotrigineTreatmentinUnipolarDepression 487
Monitoringforskinrashes,headache,dizziness, whohadfailedanECTtrialandarecenttrialof
somnolence,andgastrointestinal(GI)disturbances transcranialmagneticstimulation,reportedrobust
wascarriedouttoassesstolerancetoadjunctive moodimprovementandreliefofassociatedanxiety.
treatments [Bowden et al., 2004]. Patients were Alawyerwhohadbeennonfunctionalfor4years
instructedtostopthedrug,andtoreportrashes startedpart-timework.
immediatelyshouldtheydevelop.Allpatientsin Reportedsideeffectsweregenerallymild
Tolerance:
follow-upvisitswereaskedaboutheadache,dizziness, andtransient.Twopatientsreportedmilddrowsiness,
somnolence,andinsomnia,inadditiontoskinrashes. somnolence,anddecreaseinsexualdesire;onepatient
reportedmild transientheadachesanddizziness, and
another complainedof drymouthand nervousness.
RESULTS
One patient discontinued thetreatmentsafter8 weeks
due to thedevelopmentofa scalp rash,which wasnot
Table1displaysdemographicvariables,detailsofthe
verified.
currentillness,and data on pastfailed biological
treatmenttrials.Twelvepatients (85.7%)completed
the 6-month trialof theadjuvant treatment.Lamo-
DISCUSSION
triginedosage ranged from 50mg/day to200mg/day.
Lamotriginemayhaveantidepressant properties in
Atthetimeofaddinglamotrigine,ninepatientswere
patients withunipolar depressionand mayaccelerate
onone antidepressant(citalopramorvenlafaxine), and
the onset of action when given incombinationwith
five patientswere on twoor moreantidepressants.In
atypicalantidepressants.Large-scale, double-blind
additiontothe significant improvement ofthe core
studiesarecritically neededtoexplore furtherthe
symptoms ofdepressive symptomatology at8 weeks
efficacyand tolerability oflamotrigine treatmentin
and at6months, some patients had recognizable
unipolardepression.
clinicalimprovementwithinthefirst2weeks(Table2).
ClinicalImplications: Clinicians will(1) consider
Ontheprimaryefficacymeasureat6months,therewas
lamotrigine asanadjunct toantidepressants inTRD;
atleasta1pointchange,frommoderatelyilltomildlyill
(2)initiatelarge-scale, controlledtrials totest lamo-
atweek 8,and furtherimprovement by2points, from
trigine’sefficacyandtolerabilityinunipolardepression;
mildlyillto borderline.At 6months, four patients were
and (3)recognize that lamotrigine isgenerallyasafe
verymuchimproved,sevenweremuchimproved,onewas
drug ifpatients aremonitoredcarefully.
minimallyimproved,andtwodisplayednochangeonthe
Limitations: Limitationsincludesmall sample size,
CGI Improvement (CGI-I) subscale.Twofemale
opendesign, andheterogeneous antidepressant
patientsdiscontinued lamotrigineatweek 8:one due
that patients weretakingatthetimelamotrigine was
tothe developmentof ascalp rash, whichwas not
added.
verified,andtheotherduetotravel.Thesetwopatients
did not report significant changesorimprovements.
Table2 summarizes theefficacymeasuresfindings.
REFERENCES
Occupationaland SocialFunctioning: Eightpatients
returnedtogainfulemploymentandresumedregular BarbeeJG,JamhourNJ.2002.Lamotrigineasanaugmentation
agentin treatment-resistantdepression. JClinPsychiatry 63:
leisure activities.For example,a62-year-oldmale
737–741.
resumedplayinghockey.A55-year-oldfemalewhohad
BarbosaL,BerkM,VorsterM.2003.Adouble-blind,randomized,
suffered fromnonremitting symptomsfor 6 years, and
placebo-controlled trial of augmentationwithlamotrigineor
placeboin patientsconcomitantly treatedwithfluoxetinefor
resistantmajordepressiveepisodes.JClinPsychiatry64:403–407.
TABLE 2. Changesinefficacymeasures
BowdenCL, Asnis GM,GinsbergLD, BentleyB, LeadbetterR,
WhiteR.2004. Safetyand tolerabilityof lamotriginefor bipolar
Pairedt-test
disorder.DrugSaf27:173–184.
BowdenCL,CalabreseJR,SachsG,YathamN,AktharAS.2003.A
At8weeksAt6months
placebo-controlled18-monthtrialof lamotrigine andlithium
maintenance treatmentin recently manicor hypomanicpatients
MeasuresM(SD)df:11 t(Pr) (Pr)
withbipolarIdisorder.ArchGenPsychiatry60:392–400.
(cid:1)
Calabrese JR,BowdenCL, SachsGS, SwannAC, McElroySL,
CGI Baseline3.8(0.7)
Kusumakar V, AscherJA, Earl NL,GreenePL, MonaghanET.
8weeks2.4(0.5)
2000.A double-blind, placebo-controlled,prophylaxisstudyof
6months1.6(0.7) 9.5(.001) 12.5(.0001)
lamotrigineinrapid-cyclingbipolardisorder:Lamictal614Study
MADRSBaseline 35(6)
Group.JClinPsychiatry61:841–850.
8weeks22(7) 6.0(.001)14.0(.001)
CalabreseJR, BowdenCL,Sachs G, YathamLN,BehnkeK,
6months15(6)
MehtonenOP, Montgomery P, AscherJ, PaskaW,Earl N,
GAF Baseline49(7)
DeVeaugh-GeissJ.2003.Lamictal605StudyGroup:Aplacebo-
8weeks59(6) (cid:1)4.0(.002)(cid:1)5.0(.001)
controlled18-monthtrialoflamotrigineandlithiummaintenance
6months65(8)
treatmentin recently depressed patientswithbipolar I disorder.
(cid:1)
Baseline:priortoaddinglamotrigine.
JClinPsychiatry64:1013–1024.
DepressionandAnxietyDOI10.1002/da